Amalgamated Bank’s Avadel Pharmaceuticals AVDL Stock Holding History

Amalgamated Bank’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,807	Closed	-$60K	–	1732
2025 Q4	$60K	Sell	2,807 -391	-12%	-$7.59K	﹤0.01%	1789
2025 Q3	$49K	Hold	3,198	–	–	﹤0.01%	1843
2025 Q2	$28K	Hold	3,198	–	–	﹤0.01%	1986
2025 Q1	$25K	Hold	3,198	–	–	﹤0.01%	1986
2024 Q4	$34K	Hold	3,198	–	–	﹤0.01%	1936
2024 Q3	$42K	Hold	3,198	–	–	﹤0.01%	1895
2024 Q2	$45K	Buy	+3,198	New	+$52.1K	﹤0.01%	1875

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Amalgamated Bank's AVDL Position: Q1 2026 in Review

Amalgamated Bank sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 2,807 shares — an estimated $60K sold.

Amalgamated Bank first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $60K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Amalgamated Bank reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 2,807 Avadel Pharmaceuticals shares in Q1 2026, an estimated $60K.
Amalgamated Bank first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
Amalgamated Bank's Avadel Pharmaceuticals position peaked at $60K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.